Expiring contracts
Contracts whose period of performance ends soon. When these expire, the work usually gets recompeted — this is your pipeline of future opportunities.
Filters
Period of performance ends in (months)
0mo18mo
Contract value (obligated)
$1K$100.00B+
Agency
Set-aside
Place of performance
NAICS (prefix ok)
26 contracts ending in the next 0–18 months (0.31 seconds)
| PIID | Contractor | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|---|
| 75N91018F00003 ↗ | University Of Illinois | A DUAL AKT/PDKP1 INHIBITOR FOR ACTINIC KERATOSIS AND SKIN CANCER PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS | National Institutes Of Health | 541711 | $0 | Sep 16, 2018 | Jul 29, 2026 |
| HHSO100201700029C ↗ | Inbios International INC | POINT-OF-CARE IMMUNOASSAY FOR DIAGNOSIS OF INHALATIONAL ANTHRAX | Office Of Assistant Secretary For Preparedness And Response | 541711 | $63K | Sep 25, 2017 | Aug 30, 2026 |
| 75A50121F33014 ↗ | Battelle Memorial Institute | RTOR-BIO-AMT-1022: STUDIES IN NHP MODELS OF FILOVIRUS INFECTION: ASSAY OPTIMIZATION AND QUALIFICATION | Office Of Assistant Secretary For Preparedness And Response | 541711 | $0 | Sep 2, 2021 | Sep 1, 2026 |
| 75N95019F00088 ↗ | Sri International | TO ADMINISTRATIVELY DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2020 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2025, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS. | National Institutes Of Health | 541711 | $-11K | May 22, 2019 | Sep 11, 2026 |
| HHSO100201600030C ↗ | Emergent Product Development Gaithersburg INC. | EO14042 EMERGENT AV7909 ANTHRAX VACCINE | Office Of Assistant Secretary For Preparedness And Response | 541711 | $80.0M | Sep 29, 2016 | Sep 28, 2026 |
| 70RSAT25FR0000019 ↗ | Battelle National Biodefense Institute, LLC | TO AWARD AND FULLY FUND THE NBACC ANALYTIC TASKS FOR FACILITY SUBCONTRACTED SUPPORT AND NECESSARY UPGRADES, MODIFICATIONS, AND REPAIRS FOR 2025 (THE NBACC II EXTENSION). | Office Of Procurement Operations | 541711 | $2.2M | Sep 29, 2025 | Sep 28, 2026 |
| 70RSAT25FR0000053 ↗ | Battelle National Biodefense Institute, LLC | THIS IS A NEW TASK ORDER FOR PHYSICAL SECURITY MAINTENANCE AND UPGRADES. | Office Of Procurement Operations | 541711 | $437K | Sep 29, 2025 | Sep 28, 2026 |
| 75A50121F33005 ↗ | Battelle Memorial Institute | SCREENING POTENTIAL MEDICAL COUNTERMEASURES TO CHLORINE GAS IN A SMALL ANIMAL MODEL. | Office Of Assistant Secretary For Preparedness And Response | 541711 | $2.2M | Sep 28, 2021 | Sep 29, 2026 |
| HHSO100201600009C ↗ | Cerus Corporation | NO COST EXTENSION FOR OPTION 16 (CLIN 0018) AND REVISE KEY PERSONNEL. | Office Of Assistant Secretary For Preparedness And Response | 541711 | $-280K | Jun 16, 2016 | Sep 29, 2026 |
| 75N93022F00001 ↗ | University Of North Carolina At Chapel Hill | TASK A68 SCREENING VACCINE (AND OTHER BIOLOGICS) PLATFORM TECHNOLOGIES USING CORONAVIRUS MOUSE IMMUNOGENICITY AS A MODEL SYSTEM | National Institutes Of Health | 541711 | $564K | May 22, 2022 | Sep 30, 2026 |
| 75N93019F00131 ↗ | University Of Alabama At Birmingham | THIS TASK ORDER IS FOR THE DEVELOPMENT OF A PROTOCOL, CLINICAL TRIAL IMPLEMENTATION, CLOSEOUT AND ANALYSIS OF A PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY OF RMENB+OMV NZ (BEXSERO, GSK) IN PREVENTING N. GONORRHOEAE INFECTION. | National Institutes Of Health | 541711 | $1.4M | Aug 22, 2019 | Oct 30, 2026 |
| 70RSAT25FR0000014 ↗ | Battelle National Biodefense Institute, LLC | SECTION 2(D) - TO AWARD AND FULLY FUND THE NATIONAL BIODEFENSE ANALYSIS AND COUNTERMEASURES CENTER (NBACC) ANALYTIC TASK (AT) FOR STERILIZED LAB WASTE DISPOSAL AND SITE SERVICES FOR 2025 (THE NBACC II EXTENSION). | Office Of Procurement Operations | 541711 | $797K | May 15, 2025 | Nov 29, 2026 |
| W81XWH15C0048 ↗ | Westat, INC. | FREEZE DRIED PLASMA CLINICAL TRIAL FOR BLA RESUBMISSION. | Defense Health Agency | 541711 | $3.5M | Mar 29, 2015 | Dec 30, 2026 |
| 75N93019F00132 ↗ | The Emmes Company, LLC | CLINICAL MONITORING INITIATIVE (CMI) FOR VRC 316, 317, 320, 603 | National Institutes Of Health | 541711 | $0 | Apr 29, 2019 | Dec 30, 2026 |
| HHSO100201600017C ↗ | Dnae Group Holdings Limited | DNAE / PATHOGEN IDENTIFICATION FROM SPECIMEN, VIA CAPTURE, EXTRACTION AND SEQUENCING (PISCES) | Office Of Assistant Secretary For Preparedness And Response | 541711 | $0 | Sep 27, 2016 | Dec 30, 2026 |
| HHSN27500007 ↗ | Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | NICHD: R&D: CLINICAL TREATMENT OF NESTORONE GEL AND TESTOSTERONE GEL FOR MALE CONTRACEPTION: NON-SEVERABLE | National Institutes Of Health | 541711 | $0 | Sep 13, 2015 | Dec 30, 2026 |
| W911QY13C0056 ↗ | Dynport Vaccine Company LLC | EXTEND DEADLINE FOR TERMINATION SETTLEMENT PROPOSAL SUBMISSION DATE TO 12 MARCH 2026 UNDER TERMINATED CONTRACT FOR FDA LICENSURE OF A BIOSCAVENGER PROPHYLAXIS. | Department Of The Army | 541711 | $-317K | May 8, 2013 | Mar 10, 2027 |
| 70RSAT26FR0000002 ↗ | Battelle National Biodefense Institute, LLC | NEW FFRDC NBACC 2026 INSURANCE | Office Of Procurement Operations | 541711 | $2.6M | Mar 18, 2026 | Mar 17, 2027 |
| HHSN275201700002C ↗ | The Emmes Company, LLC | DATA COORDINATING CENTER FOR THE BEST PHARMACEUTICALS FOR CHILDREN ACT | National Institutes Of Health | 541711 | $10.7M | Jul 27, 2017 | May 27, 2027 |
| 75N93024F00002 ↗ | University Of Texas Medical Branch At Galveston | PRE-CLINICAL MODELS OF INFECTIOUS DISEASES | National Institutes Of Health | 541711 | $1.7M | Jun 24, 2024 | Jun 23, 2027 |
| 70RSAT26FR0000017 ↗ | Battelle National Biodefense Institute, LLC | NBACC II EXTENSION WORK FOR OTHERS (WFO) TASK ORDER FOR THE EQUIPMENT ACQUISITION AND DEMONSTRATION PROJECT PLANNING FOR GENERATIVE UNCONSTRAINED INTELLIGENT DRUG ENGINEERING (GUIDE), PHASE II. | Office Of Procurement Operations | 541711 | $2.0M | Jul 2, 2026 | Jul 1, 2027 |
| 75N93024F00001 ↗ | Trustees Of Tufts College | PRECLINICAL MODELS OF INFECTIOUS DISEASES | National Institutes Of Health | 541711 | $716K | Jul 10, 2024 | Jul 9, 2027 |
| HHSO100201700020C ↗ | Regeneron Pharmaceuticals INC | NO COST MODIFICATION TO REVISE THE JOINT OVERSIGHT COMMITTEE MEMBERS AND EXTEND THE PERIOD OF PERFORMANCE FOR CLIN 0001 TO SEPT 25, 2027. | Office Of Assistant Secretary For Preparedness And Response | 541711 | $-331.7M | Sep 20, 2017 | Sep 23, 2027 |
| HHSO100201700016C ↗ | Regeneron Pharmaceuticals INC | NO COST MOD TO REVISE THE CONTRACT SECTIONS: ARTICLE B.2.1., ARTICLE C.1., ARTICLE F.4, , ARTICLE G.4. AND THE STATEMENT OF WORK. | Office Of Assistant Secretary For Preparedness And Response | 541711 | $0 | Sep 29, 2017 | Sep 28, 2027 |
| HHSO100201600038C ↗ | Hoffmann-La Roche INC. | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE COST SHARE AMOUNT AND ADD SUPPLEMENTAL FUNDING TO CLIN 0002. | Office Of Assistant Secretary For Preparedness And Response | 541711 | $47.5M | Sep 14, 2016 | Sep 29, 2027 |
| HHSO100201500021C ↗ | Polynovo Biomaterials Pty Ltd | THE PURPOSE OF THIS BILATERAL ADMINISTRATIVE MODIFICATION IS TO CHANGE THE KEY PERSONNEL AND ADD AN ALTERNATE COR. 1. CHANGE ARTICLE G.2. CONTRACTING OFFICER'S REPRESENTATIVE (COR) AND ALTERNATIVE CONTRACTING OFFICER'S REPRESENTATIVE (COR) | Office Of Assistant Secretary For Preparedness And Response | 541711 | $0 | Sep 27, 2015 | Sep 29, 2027 |